NanoString Study Suggests PAM50 Recurrence Test Provides Advantages over Oncotype DX
December 14, 2011
NanoString Study Suggests PAM50 Recurrence Test Provides Advantages over Oncotype DX
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011 / Pharmacogenomics Reporter - Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group
May 18, 2011 / Pharmacogenomics Reporter - Data Supports Oncotype DX for Predicting Recurrence in Node-Positive Cancers, Guiding Radiation Therapy
March 13, 2013 / Pharmacogenomics Reporter - After 14 Percent Revenue Bump in 2012, Genomic Health Focusing on Market Growth, Prostate Dx Launch
February 13, 2013 / Pharmacogenomics Reporter - NanoString on Track to Launch Breast Cancer Subtyping Test in EU with CE Mark, in US with FDA OK
August 15, 2012 / Pharmacogenomics Reporter